share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3:募資說明書
美股sec公告 ·  05/22 22:24
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC announced the successful exercise of existing Series E and Series F warrants, resulting in $7 million in gross proceeds. The funds will primarily cover the first year of the eRapa Phase 3 trial in Familial Adenomatous Polyposis (FAP), unlocking additional non-dilutive grant funding. The exercised warrants were issued at a reduced price of $1.50 per American Depositary Share (ADS), with the ADSs being registered under an effective registration statement. In exchange for the cash exercise of the warrants, the holders received new unregistered Replacement Warrants to purchase additional ADSs. The proceeds from the warrant exercises are intended for the advancement of clinical stage assets and general corporate purposes. The Replacement Warrants, along with the shares issuable upon their exercise...Show More
Biodexa Pharmaceuticals PLC announced the successful exercise of existing Series E and Series F warrants, resulting in $7 million in gross proceeds. The funds will primarily cover the first year of the eRapa Phase 3 trial in Familial Adenomatous Polyposis (FAP), unlocking additional non-dilutive grant funding. The exercised warrants were issued at a reduced price of $1.50 per American Depositary Share (ADS), with the ADSs being registered under an effective registration statement. In exchange for the cash exercise of the warrants, the holders received new unregistered Replacement Warrants to purchase additional ADSs. The proceeds from the warrant exercises are intended for the advancement of clinical stage assets and general corporate purposes. The Replacement Warrants, along with the shares issuable upon their exercise, have not been registered under the Securities Act of 1933 and were offered to accredited investors only. Biodexa has committed to filing a registration statement for the resale of the ADSs issuable upon exercise of the Replacement Warrants. The announcement also included a reminder of the company's issued share capital and total voting rights following the warrant exercises.
Biodexa Pharmicals PLC宣佈成功行使現有的E系列和F系列認股權證,總收益爲700萬美元。這些資金將主要用於家族性腺瘤性息肉病(FAP)eRapa 3期試驗的第一年,從而解鎖額外的非稀釋性撥款。行使的認股權證以每股美國存托股票(ADS)1.50美元的降價發行,ADS是根據有效的註冊聲明註冊的。作爲兌現認股權證的交換,持有人獲得了新的未註冊替代認股權證,用於購買額外的ADS。認股權證行使的收益用於推進臨床階段資產和一般公司用途。替代認股權證及其行使後可發行的股票尚未根據1933年《證券法》註冊,僅向合格投資者發行。Biodexa已承諾提交一份註冊聲明,以轉售行使替代認股權證後發行的美國存託憑證。該公告還提醒注意該公司的已發行股本和認股權證行使後的總投票權。
Biodexa Pharmicals PLC宣佈成功行使現有的E系列和F系列認股權證,總收益爲700萬美元。這些資金將主要用於家族性腺瘤性息肉病(FAP)eRapa 3期試驗的第一年,從而解鎖額外的非稀釋性撥款。行使的認股權證以每股美國存托股票(ADS)1.50美元的降價發行,ADS是根據有效的註冊聲明註冊的。作爲兌現認股權證的交換,持有人獲得了新的未註冊替代認股權證,用於購買額外的ADS。認股權證行使的收益用於推進臨床階段資產和一般公司用途。替代認股權證及其行使後可發行的股票尚未根據1933年《證券法》註冊,僅向合格投資者發行。Biodexa已承諾提交一份註冊聲明,以轉售行使替代認股權證後發行的美國存託憑證。該公告還提醒注意該公司的已發行股本和認股權證行使後的總投票權。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。